Increase in the number of
patients suffering from various kidney disorders such as acute kidney injury
(AKI), chronic kidney disease (CKD), nephropathies, and drug-induced kidney
toxicities has led to development of novel renal biomarkers to better manage
disease progression rate. Renal biomarkers are used to localize kidney injury
(i.e., at the glomerular level, tubular level, or both) and differentiate renal
injury from pre-, post-, and non-renal injury. These biomarkers can also
predict severity of renal injury and monitor the effects of intervention.
The global Renal
Biomarkers Market is estimated to account for US$ 1,094.5 Mn in terms of
value in 2019 and is expected to reach US$ 1,894.2 Mn by the end of 2027.
Global Renal Biomarkers Market:
Drivers
Increasing demand for early
diseases diagnosis of various kidney diseases is expected to propel growth of
the global renal biomarkers market over the forecast period. Renal biomarkers
offer early diagnosis of kidney injury and provide better information about the
status of ongoing injury in patients with chronic kidney disease. These
biomarkers also forecast the probability of progression of disease, which helps
in development of personalized medicine for the treatment of chronic kidney
disease.
Global Renal Biomarkers Market:
Opportunities
Use of renal biomarkers for the
diagnosis of renal cancer is expected to offer lucrative growth opportunities
for players in the global renal biomarkers market over the forecast period.
Renal biomarkers can be effective in diagnosis of renal cancer. Currently many
clinical and laboratory algorithms are being used but there is no perfect tool
for early diagnosis of renal cancer and tumors, that are thought to be
accidently detected during routine abdominal imaging. Early diagnosis of renal
cancer can prevent disease progression.
Global Renal Biomarkers Market:
Restraints
Lack in validation of novel renal
biomarkers and their inability to correlate with clinical outcomes is expected
to hinder growth of the global biomarker. Majority of renal biomarkers
currently in use elevate too late and thus, they cannot be easily co-related
with biologic or clinical outcomes.
Moreover, renal biomarkers available today are indicative of renal function
more than being a marker of renal injury and are affected by non-renal
parameters such as gender, age, and medication status, which makes it more
difficult to manage acute kidney injury (AKI).
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3551
Key Takeaways:
Functional biomarkers segment in
the global renal biomarkers market was valued at US$ 543.6 Mn in 2018 and is
expected to reach US$ 1,057.3 Mn by 2027 at a CAGR of 7.6% during the forecast
period. Increasing products, and assay launches is expected to support growth
of the segment over the forecast period. For instance, Sphingotec launched
penKid point-of-care (POC) biomarker blood test for evaluating kidney function
in January 2020 in CE mark accepted European countries
The Enzyme Linked Immunosorbent
Assay segment held dominant position in the global renal biomarkers market in
2018, accounting for 44.3% share in terms of value, followed by
Particle-Enhanced Turbidimetric Immunoassay and Colorimetric Assay,
respectively. Enzyme Linked Immunosorbent Assay (ELISA) is immunoassay used to
identify proteins, peptides, antibodies, and hormones. Moreover, majority of
kidney biomarker tests involve use of enzyme linked immunosorbent assay
technique which is expected to support growth of the segment over the forecast
period.
The diagnostic labs segment held
dominant position in the global renal biomarkers market in 2018, accounting for
34.9% share in terms of value, followed by Outpatient Clinics and Research
Centers, respectively. Diagnostic laboratories is the primary end user where
kidney biomarker tests are performed in bulk. Physicians often recommend kidney
disease patients to have diagnostic tests performed in central diagnostic
laboratories.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/renal-biomarkers-market-3551
Market Trends
Various government organizations
offer grants for R&D in renal diseases. For instance, in September 2018,
the National Institute of Diabetes and Digestive and Kidney Diseases, a part of
Department of Health and Human Services - National Institutes of Health,
awarded Yale University grant for ‘Identification of Non-invasive Biomarkers
and Indices for Diagnosis of Drug-Induced Acute Interstitial Nephritis.
R&D of biomarkers for kidney
allergic reaction is expected to boost growth of the market. For instance, in
May 2019, researchers from Johns Hopkins Medicine (U.S) reported identifying
two protein biomarkers in urine, Urine TNF-α and IL-9’, for effective diagnosis
of acute interstitial nephritis.
Global Renal Biomarkers Market:
Competitive Landscape
Major players operating in the
global renal biomarkers market include, Beckman Coulter, Inc., (Danaher
Corporation), Thermo Fisher Scientific Inc., Abbott Laboratories, BIOPORTO A/S,
Astute Medical, Inc., Randox Laboratories Ltd., and SphingoTec GmbH.
Global Renal Biomarkers Market:
Key Developments
January 2020: Hitado GmbH, a
Sysmex point-of-care subsidiary, and SphingoTec GmbH signed an exclusive
distribution agreement for the commercialization of the Nexus IB10 diagnostic
platform, a fully automated rapid immunoassay point-of-care platform by Hitado,
in Germany
October 2019: Antech Diagnostics
acquired Biovet, a biotechnology company that offers diagnostic solutions for
animal health
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3551
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment